| Patient | Sarah Walker |
|---|---|
| Date of birth | 1976-12-23 |
| Identifiers | MRN HR-ET019-SYN; SSN (made up) 000-19-7062 |
| Document date | 2026-06-08 |
| Author | Harriet Okonjo-Bell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Madam Walker is a 49-year-old company founder with hypertension and chronic kidney disease G3a A2 who comes for her yearly preventive visit six weeks after her eleven-week review. Amlodipine was added then, and her home readings now average 127/80. She has had no ankle swelling, dizziness or genital itching. She restarted losartan and empagliflozin after the stomach illness two months ago and has had no further trouble. She has been on the road three weeks out of four, sleeping six hours on travel nights. She is using the salt-free seasoning at home and asking for sauces on the side at banquets. She wants to know which screening tests she needs and when, so that she can fit them between trips. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 49 |
| Home blood pressure | Average 127/80 on losartan 100 mg and amlodipine 5 mg |
| Travel | Three weeks in four |
| Mood | PHQ-2 0 |
Health risk assessment. Completed on the patient portal before the visit and reviewed with her by Dr. Okonjo-Bell. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good |
| Psychosocial | Busy and purposeful; stress from the pace of work, which she manages and does not want to give up |
| Substance use | No tobacco or drugs; a glass of wine at some events (AUDIT-C 1) |
| Physical activity | Walks during layovers and on home mornings, about 120 minutes a week |
| Nutrition | Salt-free seasoning at home; sauces on the side and no added salt on the road; water in place of a third coffee |
| Sleep | Six hours on travel nights, seven at home |
| Food and housing | Secure |
| Safety | Seat belt always; feels safe at home |
| Health care experiences | Wants the numbers and the reasons; satisfied that her plan fits her work |
| Activities of daily living | Independent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight change; weight down 2.4 kg since intake |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No hoarseness |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Stomach illness resolved; no blood in the stool |
| Genitourinary | Negative | No burning, itching or discharge; periods becoming irregular |
| Breast | Negative | No lump, skin change or nipple discharge |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No changing moles; no scalp or hair problems |
| Neurological | Negative | No headaches since her blood pressure came down |
| Psychiatric | Negative | Mood steady; PHQ-2 0 |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Losartan 50 mg oral tablet, one tablet each morning | One tablet each morning, at the same home time when traveling | Oral route | 2026-02-23 to 2026-03-09 | completed | S |
| Losartan 100 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-03-09 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery | One tablet each morning, with sick-day rules | Oral route | 2026-02-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-23 | active | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet on the tongue every 8 hours as needed for nausea, for up to two days | Every 8 hours as needed for nausea, up to two days | Oral route | 2026-04-13 to 2026-04-15 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-27 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-08 | Body height | 163 | cm | S |
| 2026-06-08 | Body weight | 76.6 | kg | S |
| 2026-06-08 | Body mass index (BMI) [Ratio] | 28.8 | kg/m2 | S |
| 2026-06-08 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-06-08 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-06-08 | Heart rate | 74 | /min | S |
| 2026-06-08 | Respiratory rate | 16 | /min | S |
| 2026-06-08 | Body temperature | 36.7 | Cel | S |
| 2026-06-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-08 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-06-08 | Total score [AUDIT-C] | 1 | {score} | S |
Vital signs recorded on 2026-06-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 76.6 kg, BMI 28.8; blood pressure 126/80 |
| Eyes | Visual acuity 20/20 in each eye with reading glasses for near |
| Mouth | Teeth and gums healthy |
| Neck | No thyroid enlargement |
| Cardiovascular | Regular rhythm; no murmur; no ankle swelling |
| Respiratory | Clear |
| Breast | Examined with a female chaperone and her agreement: no masses, skin changes or nipple discharge |
| Abdomen | Soft, non-tender |
| Skin | No suspicious lesions |
| Psychiatric | Engaged and direct |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigated | resolved | confirmed | R80.9 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressure | active | confirmed | I12.9 | S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis. |
| Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 2021 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6% | active | confirmed | N18.31 | S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease. |
| Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate) | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Viral gastroenteritis after a sales convention, with mild volume depletion and losartan and empagliflozin held under her sick-day rules; no acute kidney injury; resolved | resolved | confirmed | A08.4 | S — Synthetic intercurrent illness; not a historical claim. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure | Completed today | 126/80 mmHg; home average 127/80 |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C 1 |
| Tobacco use | Completed today | Never |
| Breast cancer screening | Ordered | Mammogram every two years from 40; booked in two weeks on a day she is home |
| Cervical cancer screening | Completed today | Primary HPV test every five years from 30, her choice |
| Colorectal cancer screening | Ordered | From 45; stool immunochemical test yearly, her choice so that she can mail it while traveling; colonoscopy discussed |
| HIV screening | Up to date | Negative with the kidney evaluation in February |
| Hepatitis C screening | Up to date | Negative with the kidney evaluation in February |
| Hepatitis B screening | Up to date | Surface antigen negative, no immunity, in February; vaccination started today |
| Diabetes screening | Up to date | A1c 5.4% at intake |
| Statin for prevention | Up to date | Atorvastatin 20 mg since February; LDL 98 mg/dL |
| Healthy diet and physical activity counseling | Completed today | Sodium plan with the dietitian; walking during layovers |
| Pneumococcal vaccine | Completed today | PCV20 for chronic kidney disease |
| Tdap | Completed today | No booster within ten years |
| Hepatitis B vaccine | Completed today | Dose 1 of 2 (HepB-CpG) |
| Recombinant zoster vaccine | Due | From 50, after her birthday |
| Influenza and COVID-19 vaccines | Due | Influenza given in February; both due in the autumn |
| Eye examination | Due | Mild hypertensive retinopathy at intake; dilated examination by an optometrist yearly |
| Osteoporosis screening | Not indicated | Not yet postmenopausal and no risk factors that call for earlier screening |
Immunizations given today: Pneumococcal conjugate vaccine PCV20; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap); Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]
Guideline basis: Adult Immunization Schedule by Age (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Cervical Cancer: Screening (2018); Colorectal Cancer: Screening (2021); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations, United States, 2023 (2023)
Follow-up: Mammogram in two weeks; stool test by mail; HPV result by the portal. Six-month review in ten weeks with urine albumin, kidney function, hemoglobin, the PHQ-9 and the second hepatitis B dose. Next preventive visit in one year. Next scheduled visit 2026-08-17: six-month review: blood pressure at goal, urine albumin, kidney function, hemoglobin, mood, and the travel season ahead. [S]
Voluntary advance care planning discussion of about 20 minutes, with her consent. She wants full treatment of any illness that could be reversed, including dialysis if her kidneys ever failed, and wants to be told plainly what is happening at every stage. She has named a health care agent, recorded in the confidential part of the chart and not named here, and has a will and business succession plan in place through her company. She chose not to record other treatment preferences today. To be revisited yearly or after any serious illness. [S]